Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation
Table 1
Summary of biochemical selectivity testing of ADAM17 inhibitors against a panel zinc of metalloproteases. Synthetic substrates were used for all assays. All results are IC50, μM.
